ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More
ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More
In addition, the company is currently finalizing an agreement with a much larger FDA-registered product manufacturing facility that can help scale Vitastem product inventory to over 100,000 units with just 6-8 weeks lead time. This move is imperative to the company's success in being able to fulfill increased customer demand throughout the US and around the world.LOS ANGELES, July 06, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is very pleased to announce several exciting business updates for current and prospective shareholders, partners, and healthcare providers.
洛杉磯，2023年7月6日(Global Newswire)--ViaDerma，Inc.(場外交易市場代碼：VDRM)非常高興地為現有和潛在的股東、合作夥伴和醫療保健提供者宣佈了幾項令人興奮的業務更新。
The company is currently over 30% through the process of our stability testing requirements in order to finalize approvals for distributing lead product Vitastem Ultra throughout multiple countries in the Caribbean and Middle East. Based on the feedback we have received to date, we anticipate that the required testing protocols should be completed by the end of August or in early September of this year.
該公司目前通過我們的穩定性測試要求的過程超過30%，以便最終批准分銷鉛產品VitaStem超遍佈加勒比海和中東的多個國家。根據我們迄今收到的反饋，我們預計所需的測試方案應在今年8月底或9月初完成。
Our new hair regrowth product, Nupelo, is in the final stages of receiving FDA-registered product approval. Recently, our team received feedback and a new request by the FDA to submit additional information required for final approvals. The requirements were sent back to the FDA in early June and we are awaiting the confirmation for FDA-registered approval for Nupelo any day now.
我們的新頭髮再生產品，努佩洛，正處於獲得FDA註冊產品批准的最後階段。最近，我們的團隊收到了FDA的反饋和新的要求，要求提交最終批准所需的額外資訊。這些要求已於6月初送回FDA，我們正在等待Nupelo在FDA註冊批准的確認。
In addition, the company is currently finalizing an agreement with a much larger FDA-registered product manufacturing facility that can help scale Vitastem product inventory to over 100,000 units with just 6-8 weeks lead time. This move is imperative to the company's success in being able to fulfill increased customer demand throughout the US and around the world.
此外，該公司目前正在與一家在FDA註冊的更大的產品製造工廠敲定一項協定，該協定可以幫助將Vitastem的產品庫存擴大到10萬臺以上，交貨期僅為6-8周。這一舉措對於該公司能夠在美國和世界各地成功滿足日益增長的客戶需求至關重要。
The company has been working very hard to overcome several scalability challenges we had unexpectedly encountered with our previous product manufacturer who proved unable to fulfill the needed product inventory fast enough in order to meet the volume requirements demanded from healthcare providers and medical supply distributors. Since then, management has thoroughly researched, vetted, and sourced a new Tier-1 FDA-registered medical product manufacturer here in the US who will soon take over all of the manufacturing requirements for Vitastem Ultra. This strategic move will drastically help ViaDerma scale the business much more successfully moving forward in order to meet the increased demand by healthcare professionals and health care supply distributors that have been attributed to our ongoing sales & marketing efforts throughout the world.
該公司一直在非常努力地克服我們之前的產品製造商意外遇到的幾個可擴展性挑戰，事實證明，這些製造商無法足夠快地滿足所需的產品庫存，以滿足醫療保健提供商和醫療用品分銷商的批量要求。從那時起，管理層已經對一家在美國FDA註冊的新的一級醫療產品製造商進行了徹底的研究、審查和採購，該製造商將很快接管Vitastem Ultra的所有制造要求。這一戰略舉措將極大地幫助ViaDerma更成功地擴大業務規模，以滿足醫療保健專業人員和醫療保健用品分銷商不斷增長的需求，這些需求歸功於我們在世界各地的持續銷售和營銷努力。
Furthermore, over the past several weeks, the company has interviewed several auditors, CPA firms, and attorneys with the expectations of retaining their services very soon in order to complete the two years of audited financial statements required to become fully SEC reporting. Once completed, the company plans to immediately apply for uplisting ViaDerma to the OTCQB.
此外，在過去的幾周裡，該公司採訪了幾名審計師、註冊會計師事務所和律師，希望他們很快就能保留他們的服務，以便完成兩年的審計財務報表，這是完全報告美國證券交易委員會所需的。一旦完成，該公司計劃立即申請將Viaderma提升到OTCQB。
ViaDerma is deeply committed to expanding the growth of our business to great new heights in 2023 and even more so into 2024 and beyond. Feedback from healthcare providers in the US and abroad has been stellar and the demand for Vitastem as a go-to topical antibiotic for minor to severe wounds and infectious skin diseases continues to increase by the day.
真皮病毒堅定地致力於在2023年將我們的業務增長擴大到新的高度，甚至到2024年及以後。來自美國和海外醫療保健提供者的反饋一直很好，作為治療輕微到嚴重傷口和感染性皮膚病的首選局部抗生素的Vitastem的需求每天都在繼續增加。
The company's management team deeply appreciates the ongoing feedback and patience from shareholders, partners, and healthcare providers. We are extremely grateful and excited about the future of the business over the next year and look forward to sharing several more updates as soon as possible.
公司管理團隊對股東、合作夥伴和醫療保健提供者不斷提供的反饋和耐心深表感謝。我們對未來一年的業務前景感到非常感激和興奮，並期待著儘快分享更多的更新。
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit:
關於ViaDerma公司
ViaDerma公司(場外交易代碼：VDRM)是一家上市的專業製藥公司，致力於將新產品推向市場，並向目前各種治療領域的製藥業領先者提供其創新的經皮給藥技術解決方案。如需更多資訊，請訪問：
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management's beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
根據證券法，任何對未來業績的預測都是“前瞻性陳述”。納入這類陳述是為了讓潛在投資者有機會了解管理層對未來的信念和意見，以便他們可以將這些信念和意見作為評估投資的眾多因素之一。
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
Follow ViaDerma on Twitter:
Follow ViaDerma on Facebook:
聯繫方式：
投資者關係
電子郵件：ir@viaderma.com
電話：310-734-6111
在Twitter上關注Viaderma：
在Facebook上關注ViaDerma：
譯文內容由第三人軟體翻譯。
